Instead of automatically ruling out immunotherapy for cancer patients with co-existing autoimmune diseases like rheumatoid arthritis, oncologists collaborate with experienced rheumatologists. This specialist team can assess the patient's specific condition, manage risks, and confidently advise whether it is safe to proceed with anti-PD-1 therapy, enabling more patients to access effective treatments.

Clinicians must weigh the immediate benefits of adding a PD-1 inhibitor for non-muscle-invasive bladder cancer against the potential loss of efficacy for crucial systemic therapies like EV-pembro if the disease later becomes metastatic. This introduces a new layer of long-term treatment strategy from the first diagnosis.

While adding PD-1 inhibitors to standard BCG therapy in high-risk non-muscle-invasive bladder cancer improves event-free survival, it also introduces significant Grade 3 toxicity (around 24%) without mature overall survival data, making its risk-benefit profile questionable.

The POTOMAC trial's success adding durvalumab to BCG for non-muscle invasive bladder cancer introduces a major logistical hurdle. Urologists, who typically manage these patients, often lack the expertise to handle systemic immunotherapy side effects, creating uncertainty about which specialty will administer this new standard of care.

With highly effective neoadjuvant therapies now available, the surgeon's role in muscle-invasive bladder cancer is evolving. They are moving from being the primary decider and treater to being a key manager of a 'perioperative bundle,' where their first goal is often to get patients to medical oncology for systemic treatment.

When managing toxicities from trastuzumab deruxtecan (TDXD) in urothelial cancer, clinicians should refer to established protocols and literature from breast cancer, where experience is more extensive. This cross-disciplinary approach is necessary for managing side effects like nausea, vomiting, and lung disease until more bladder cancer-specific data becomes available.

In high-risk non-muscle invasive bladder cancer (NMIBC), trials like CREST and POTOMAC show adding a systemic immune checkpoint inhibitor to BCG therapy introduces significant toxicity. The benefit is primarily in local control, which may not justify the risk, especially with other effective intravesical options available.

Despite data from kidney cancer showing immunotherapy re-challenge is often ineffective, oncologists admit to using it in urothelial cancer. This highlights a clinical conflict where the desire to use a powerful drug class outweighs the lack of supporting evidence, especially in specific, confusing patient scenarios.

While an approved option, systemic checkpoint inhibitors like pembrolizumab come with a significant downside. Clinicians counsel patients on a 15% chance of life-altering toxicities like permanent endocrine disease, a critical risk when the treatment often only delays, not prevents, cystectomy.